Sanofi Acquires Haemophilia Specialist Bioverativ for US$11.6 B
By Subham Nandi
Pharma Deals Review: Vol 2018 Issue 1 (Table of Contents)
Published: 31 Jan-2018
DOI: 10.3833/pdr.v2018.i1.2299 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Sanofi has agreed to acquire haemophilia specialist Bioverativ for US$105 per share, equating to a deal value of US$11...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS